局部进展期或晚期肛管鳞癌的诊疗进展
Progress in diagnosis and treatment of locally advanced or metastatic stage anal squamous cell carcinoma
马晓婷 1王晰程 1巴一1
作者信息
- 1. 中国医学科学院北京协和医院 肿瘤医学中心,北京 100730
- 折叠
摘要
肛管鳞癌(ASCC)是一种罕见的恶性肿瘤,大约 90%的患者可归因于人乳头瘤病毒(HPV)感染.随着发病率和死亡率的逐年上升,关于ASCC的治疗方案也在不断探索.目前,局部进展期ASCC的标准治疗为放化疗,复发性或转移性ASCC目前仍采取含铂联合方案化疗作为标准治疗.随着包括放化疗、靶向治疗、免疫治疗和基于生物标志物的治疗在内的新型联合治疗策略的出现,ASCC的治疗策略也在不断改进.文章综述了局部进展期和转移性ASCC的诊疗进展,以期为临床诊疗提供参考意见.
Abstract
Anal squamous cell carcinoma(ASCC)is a rare malignant tumor,with approximately 90%of patients attributed to human papilloma virus(HPV)infection.With the increase of incidence rate and mortality year by year,treatment options for ASCC are constantly being explored.At present,the standard treatment for locally advanced ASCC is chemoradiotherapy,while platinum containing combination chemotherapy is still used as the standard treatment for recurrent or metastatic ASCC.With the emergence of new combination strategies including chemoradiotherapy,targeted therapy,immunotherapy,and biomarker based therapy,the therapeutic prospects of ASCC are also rapidly developing.The article reviews the diagnostic and therapeutic progress of locally advanced and metastatic ASCC,in order to provide reference for clinical diagnosis and treatment.
关键词
肛管鳞癌/人乳头瘤病毒/放化疗/免疫治疗Key words
Anal squamous cell carcinoma/Human papilloma virus/Chemoradiotherapy/Immunotherapy引用本文复制引用
基金项目
中国医学科学院医学与健康科技创新工程(2023-I2M-3-012)
出版年
2024
NETL
NSTL
万方数据